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Background/aim: The aim of the study was to evaluate the relationship between primary tumor type and the effectiveness of microwave
ablation (MWA) therapy by comparing the technical and clinical outcomes of MWA in the treatment of colorectal liver metastases
(CLM) and noncolorectal liver metastases (NCLM).
Materials and methods: Between January 2019 and March 2021, 47 consecutive patients (25 male, 22 female) with a total of 63
unresectable hepatic metastases underwent MWA under ultrasound guidance. The patients were divided into CLM (n = 29) and NCLM
(n = 18) groups. Patient demographics, procedural details, and complications were noted. The overall survival (OS) and disease-free
survival (DFS) rates were also analyzed.
Results: Technical success was 100% in both groups. No major complication was observed. Three minor complications [fatigue (n = 2)
and subcutaneous hematoma (n = 1)] were encountered. DFS rates were 88.9%, 71.9%, 64.9%, and 44.0% at 3, 6, 12, and 24-months,
respectively, with a mean DFS of 17.4 months (95% CI: 15.1, 19.7). Also, OS rates were 93.7%, 90.0%, 76.8%, and 64.3%, at 3, 6, 12, and
24-months, respectively, with a mean OS of 18.5 months (95% CI: 16.2, 20.7). There was no significant difference in recurrence between
the CLM and NCLM groups (p = 0.452). The recurrence rate in liver metastases > 3 cm in size was significantly higher than in metastases
≤ 3 cm in size (p < 0.001).
Conclusions: MWA therapy is as effective in the NCLM group as in the CLM group, regardless of histologic type. Metastasis size (>3
cm) was correlated with the recurrence rate in the CLM and NCLM groups.
Key words: Microwave ablation, metastasis, liver, ultrasound, thermal ablation

1. Introduction
Though metastatic liver tumors are associated with
increased mortality and morbidity, clinical outcomes of
patients with liver metastases improved greatly in recent
years [1]. After lymph nodes, the liver is the second most
common organ with metastases [2]. The most common
metastases to the liver are caused by colorectal cancer
(59%), with more than one segment being affected in 80%
of cases [3]. Surgery is the gold standard treatment method
in liver metastasis; however, it can only be performed
in 20% of metastatic liver lesions [4,5]. The majority of
liver malignancies cannot be surgically treated due to
the presence of comorbid diseases, multiple metastases,
anatomic localization precluding resection, insufficient
functional liver capacity, and tumor recurrence [6,7].
Many physicians and patients also prefer interventional
therapies due to the lower mortality and morbidity risks

compared to surgery [8]. The combination of thermal
ablation therapies with surgical resection offers a high
cure probability in eligible patients [9]. Various ablation
methods have been developed, including radiofrequency
ablation (RFA) and microwave ablation (MWA), and both
can be done percutaneously with imaging guidance [10].
Compared to RFA, MWA has several advantages such as
shorter ablation times, larger ablation areas, the lower heat
sink effect, and no need for grounding pads [11].
Percutaneous MWA is a safe and effective method
in the treatment of both primary and metastatic hepatic
malignancies that are not suitable for surgery [12]. Also,
high success rates have been reported in the treatment of
MWA up to 5.5 cm in colorectal tumor metastases [13].
However, there are few studies on the efficacy of MWA
therapy in noncolorectal liver metastases [14]. This study
aims to evaluate the relationship between primary tumor
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type and the effectiveness of microwave ablation (MWA)
therapy by comparing the technical and clinical success of
MWA therapy for colorectal liver metastases (CLM) and
noncolorectal liver metastases (NCLM).
2. Materials and methods
2.1. Participants
This retrospective study was conducted in compli
ance with the principles of the Helsinki declaration, and
informed consent was obtained from each patient. Ethical
approval for this retrospective study was obtained from
the Institutional Review Board (2021-21460-217). Patients
with metastatic liver disease who were referred to our
clinic for thermal ablation between January 2019 and
March 2021 were included in the study after obtaining
their informed consent.
An oncology committee consisting of radiologists,
oncological surgeons, gastroenterologists, medical
oncologists, radiation oncologists, and nuclear medicine
specialists made all decisions about MWA therapy on a
multidisciplinary. Inclusion criteria were as followed; (i)
ineligible for surgery due to comorbidities, (ii) anatomical
localization where surgical treatment is not feasible
or safe, (iii) insufficient functional liver capacity after
surgery (especially in recurrent surgical procedures),
(iv) the patient’s refusal to undergo surgery. Exclusion
criteria were; (i) presence of extrahepatic metastases, (ii)
pregnancy, (iii) uncorrectable coagulopathy.
A total of 47 patients with 63 lesions met the above
criteria and were enrolled in this study. The patients were
divided into two groups as CLM and NCLM. Therewithal,
to determine how tumor size affected the recurrence rates,
the lesions were classified into two groups: ≤3 cm lesions
and >3 cm lesions. Also, the location of liver metastases
was noted.
2.2. Ablation procedures
One interventional radiologist with 7-years’ experience on
interventional oncology performed all procedures. MWA
was performed in all patients under deep sedoanalgesia
under the supervision of an anesthesiologist. Under
sterile conditions, local anesthesia was applied to the
subcutaneous area and the liver capsule with 10 cc of
prilocaine (Priloc 2%, Vem Pharmaceuticals, Turkey).
Lesions were accessed under ultrasound guidance (Esaote
MyLab Seven, China) with a convex probe. The Eco
(Nanjing Eco System, China) device, which works with
a frequency of 2.45 GHz, is shaft-cooled and continuous
energy transferring, was used for MWA. Considering
the location and size of the lesion, 14-16-17-gauge MWA
antennas were used. Similarly, the ablation procedure was
performed at varying power and duration depending on
the size of the lesion. Successful treatment was defined as
ablation of the tumor with a 10 mm margin, preserving

intact parenchyma and nontarget tissues [15] (Figure 1).
In 21 patients, additional hydrodissection with 0.9% saline
solution was required for the lesions that were close to the
bowel loops, diaphragm, and large vessels (if closer than 5
mm) [16]. The technical success of MWA was defined as
the depiction of complete ablation at the multiphasic CT
performed one day after the procedure.
2.3. Evaluation of tumor response
The modified Response Evaluation Criteria in Solid
Tumors (mRECIST) were used to evaluate the ablation
procedure. Adverse events and complications after
treatment are classified according to the SIR (Society of
Interventional Radiology) adverse event classification
[17]. The local tumor progression (LTP) was described
as the detection of nodular enhancement in the adjacent
ablation zone during follow-up.
2.4. Follow-up of patients
The multiphasic computed tomography (CT) (64row multidetector CT, Aquilion 64; Toshiba Medical
Systems, USA) examination was performed every three
months for the first year and then every six months
thereafter. The postprocedural ablation zone diameter
ratio to preprocedural tumor diameter was calculated
on CT images one day after the procedure. Follow-up
imaging was performed with multiphasic CT or PET CT
(Figures 2–3). If the CT findings were equivocal, magnetic
resonance imaging and/or PET-CT were performed for
confirmation.
2.5. Statistical analysis
Statistical analyzes were performed with the SPSS 13.0
Statistical Software (SPSS Inc., Chicago, IL, USA). As
statistical analysis, for descriptive statistics, categorical
variables were presented with the number, percent, and
continuous variables with mean ± standard deviation and
median (minimum and maximum) values. Pearson’s chisquare test was used for the comparison of categorical
variables. Continuous variables were compared with
nonparametric (Mann-Whitney U test) and parametric
(Student’s t-test) methods according to their conformity
to normal distribution evaluated using the KolmogorovSmirnov tests. The Kaplan–Meier survival curves were
used for survival analysis. The statistical significance level
was accepted as p < 0.05.
3. Results
The data of 39 lesions in 29 patients (22 males, 7 females)
with CLM and 24 lesions in 18 patients (3 males, 15
females) with NCLM were analyzed. The characteristics
of the patients are shown in Table 1. Complete ablation
was observed in all lesions in control CT one day after
the ablation procedure. The mean age of the patients with
CLM and patients with NCLM were 64.1 ± 8.9 and 50.7
± 9.2 years, respectively. The mean age was significantly
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Figure 1. Ultrasound images of a 61-year-old male patient show a 35 mm hyperechoic colon cancer metastasis
in liver segment 6 (red arrows) (a), placement of the microwave ablation probe in the metastasis (b), and
ablation process (c).

Figure 2. PET CT images of a 61-year-old female patient show gastric cancer metastasis in liver segment 4A (a)
and no metabolic activity in ablation zone consistent with complete response after microwave ablation therapy
(b).

higher in the patients with CLM than in the patients with
NCLM (p < 0.001). The primary tumors of the patients
are presented in Table 2. Six patients had two metastatic
lesions, and five patients had three metastatic lesions. The
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mean lesion sizes were 27.2 ± 15.8 mm and 23.7 ± 12.3 mm
for CLM and NCLM groups, respectively. There was no
statistically significant difference between the two groups
in terms of lesion sizes (p = 0.163).
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Figure 3. PET CT images of a 60-year-old male patient show colon cancer metastasis in liver segment 4A-8 junction level
(a) and metabolic activity after microwave ablation therapy in the edge of ablation zone consistent with recurrence (b).
Table 1. Patient characteristics.
Variables

Total
(47 patients with 63 lesions)

CLM
(29 patients with 39 lesions)

NCLM
(18 patients with 24 lesions)

Mean age (years)

59 ± 11.1

64.1 ± 8.9

50.7 ± 9.2

Sex (male/female)

25/22

22/7

3/15

Near the larger vessels (n, %)

5 (7.9%)

3 (7.7%)

2 (8.3%)

Near gastrointestinal tract (n, %)

3 (4.8%)

3 (7.7%)

-

Near diaphragm (n, %)

6 (9.5%)

4 (10.2%)

2 (8.3%)

Near liver capsule (n, %)

5 (7.9%)

4 (10.2%)

1 (4.2%)

Near gallbladder (n, %)

2 (3.2%)

1 (2.6%)

1 (4.2%)

No special (n, %)

42 (66.7%)

24 (61.6%)

18 (75%)

Location of liver metastasis

CLM: colorectal liver metastases, NCLM: noncolorectal liver metastases, Near: closer than 5 mm

There were five (7.9%) lesions located near large vessels,
three (4.8%) lesions located close to the gastrointestinal
tract, six (9.5%) lesions adjacent to the diaphragm, five
(7.9%) lesions located near the liver capsule and two (3.2%)
lesions located near the gallbladder. The hydrodissection
was performed on 21 lesions.
A 16-G, 14-G, and 17-G antennas were used in 44
(69.8%), 12 (19.0%), and 7 (11.2%) lesions, respectively.
The mean applied power was 40 ± 4.4 watts. The mean
ablation time was 4 ± 1.6 min. The ratio of the diameter of
the ablation zone to the tumor diameter was 1.72 ± 0.56 in
lesions with no recurrence and 1.37 ± 0.45 in lesions with
recurrence (p = 0.173).
Three patients had grade A complications according to
the SIR adverse event classification (6.4%). Two of these
patients had fatigue for 2 days after the MWA procedure. A

subcutaneous hematoma was encountered at the insertion
site of the ablation probe, which did not require transfusion
and resolved spontaneously.
The mortality rate was 24.1% (7 of 29 patients) in
the CLM group; the causes of death for patients were
extrahepatic metastases (n = 4), cardiovascular events (n =
2), and local tumor progression (n = 1). Also, the mortality
rate was 22.2% (4 of 18 patients) in the NCLM group; the
causes of death for patients were extrahepatic metastases
(n = 2), cerebrovascular event (n = 1), and local tumor
progression (n = 1).
The median follow-up time was 9 (range 3–24) months.
The 3-, 6-, 12-, 24- months disease free survival (DFS) rates
were 88.9%, 71.9%, 64.9% and 44.0%, respectively, with a
mean DFS of 17.4 months (95% CI: 15.1, 19.7). The 3-, 6-,
12-, 24- months overall survival (OS) rates were 93.7%,
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Table 2. Primary tumors of the patients.
n

%

Colon

20

42.5

Rectum

9

19.1

Breast

6

12.8

Gastric

4

8.5

Ovarian

3

6.4

Pancreas

3

6.4

Cervix

2

4.3

CLM

NCLM

CLM: colorectal liver metastases, NCLM: noncolorectal liver
metastases

90.0%, 76.8% and 64.3%, respectively, with a mean OS of
18.5 months (95% CI: 16.2, 20.7) (Figure 4).
Fifteen of the 39 CLM (38.5%) and 7 of the 24 NCLM
(29.2%) had recurrence during follow-up. There was no
significant difference in terms of recurrence between
the two groups (p = 0.452). Moreover, 12 of the 46 liver
metastasis with a tumor size of ≤3 cm (26%) and 10 of
the 17 liver metastasis with a tumor size of >3 cm (58.8%)
had recurrence after MWA. The recurrence rates were
significantly higher in liver metastasis with a tumor size
of >3 cm than in lesions with a tumor size of ≤3 cm (p <
0.001) (Table 3).
4. Discussion
Parenchyma-preserving methods are increasingly adopted
in the primary or metastatic cancers of the liver [18].

Although there are studies in the literature reporting that
partial hepatectomy offers better OS and DFS than thermal
ablation methods, it should be considered that the bias
caused by the performing of thermal ablation methods on
patients who are not suitable for surgery may influence the
results [19]. Also, surgical and thermal ablation methods
have provided similar OS and DFS for recurrent liver
metastases after partial hepatectomy [19]. Therefore, the
prospective COLLISION trial results will provide a more
accurate comparison of resection and ablation methods
in similar lesions [20]. It has been reported that while
MWA has similar clinical success to surgical resection in
liver metastases, the complication rate is lower [21,22]. On
the other hand, thermal ablation methods in patients not
suitable for resection can provide a longer lifespan than
chemotherapy alone [13,23]. In addition, MWA can make
the lesion suitable for surgery by downstaging the initially
unsuitable lesion [24,25].
Tilborg et al. revealed that MWA was effective in the
treatment of unresectable CLM [26]. Moreover, Yuan et al.
reported that thermal ablation was safe and effective for
treating liver metastases of gynecological tumors [27]. Izzo
et al. reported no significant difference between colorectal
and noncolorectal metastases in recurrence and survival
after MWA therapy [28]. Groeschl et al. reported that liver
recurrence rates after MWA as 36.3% in CLM and 30.7%
in NCLM and independent of tumor histology (except
neuroendocrine tumor metastases), liver recurrences after
MWA were closely related to tumor size and the number of
tumors ablated [29]. In the current study, recurrence rates
after MWA in the liver were 38.5% (15/39) in CLM and
29.2% (7/24) in NCLM, and it was higher in metastases
with >3 cm. Li et al. reported that tumor diameter was
an independent factor predicting LTP [30]. Therewithal,
MWA is effective in liver metastases up to 5.5 cm [31].

Figure 4. Disease-free survival (DFS) and overall survival (OS) in hepatic metastases.
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Table 3. Comparison of recurrence rates by tumor type and size. 10 (58.8%)
Tumor type

Recurrence (n, %)

CLM (39)

NCLM (24)

15 (38.5%)

7 (29.2%)

P* value
0.452

Tumor size
≤3 cm (46)

>3 cm (17)

12 (26%)

10 (58.8%)

P* value
<0.001

*Mann-Whitney U test, CLM: colorectal liver metastases, NCLM: noncolorectal liver metastases

It has been reported that the 1-, 2-year DFS and OS
rates were 65.9%, 31.5%, and 81.8%, 60.8%, respectively,
for MWA of hepatic metastases [30]. The current study
revealed that the 1-, 2-year DFS and OS rates were 64.3%,
42.9%, and 77.5%, 61.6%, respectively, for MWA of hepatic
metastases.
MWA emerged after RFA as a new therapy, and it is
a safe and effective treatment method in primary and
metastatic cancers of the liver [12]. It has been shown
that MWA is superior to RFA in local tumor control in
metastatic liver tumors [32,33]. However, no significant
difference was found between RFA and MWA with regard
to disease-free survival, local tumor progression, and
sufficient ablation zone [34]. Remp et al. reported that LTP
emerged at the edge of the ablation zone [35]. Therefore,
successful ablation is only possible by properly positioning
an appropriate antenna in the lesion, reaching an adequate
temperature inside the lesion, and confirming that the
ablation zone is sufficient. In this study, complete ablation
was observed in all lesions in control CT one day after the
ablation procedure. Previous research has addressed the
importance of the safety margin of tumor ablation. In this
study, the postprocedural ablation zone diameter ratio to
preprocedural tumor diameter was evaluated; however,
there was no significant difference between these rates.
In MWA, tumors located closer than 5 mm to critical
organs, such as the intestinal system and great vessels,
have a high risk for complications [16]. On the other
hand, failure to create sufficient ablation zones to avoid
complications during the ablation procedure of tumors
in these localizations can reduce the technical success
of the procedure and cause an increase in recurrence/
residual tumor [36]. Different techniques have been
used to overcome this issue, and the most common is
hydrodissection. In the current study, hydrodissection
was performed on 21 lesions, and none developed any
complications. In the hydrodissection method, 0.9%
saline or dextrose is percutaneously injected between the
critical anatomical structure and the tumor. The ablation
procedure is initiated after a sufficient safety gap is

established [37]. Different commercial products, such as
hyaluronic acid and poloxamer gel are also available for
this purpose [38,39].
In malignant liver tumors, the major complication
rate of MWA therapy has been reported to be 2.6%–2.9%
[32,40]. Major complications are considered intestinal
tract injury, major vessel injury, major biliary duct injury,
bleeding requiring embolization, liver abscess, and tumor
seeding. The minor complication rate of MWA therapy has
been reported as 5.7%––7.3% [32]. The most common side
effects related to the procedure are fever and general fatigue.
In the current study, no major complication was observed,
and the rate of minor complications (SIR classification
grade A) was in accordance with the literature (6.4%).
This study has several limitations. First, the
retrospective nature of this study might have influenced
the results. Second, the sample size was also relatively
small. Third, long-term follow-up results were lacking.
There is a need for larger, prospective, and longer followup studies on this subject.
5. Conclusion
In conclusion, MWA therapy is as effective in the NCLM
group as in the CLM group, regardless of histologic type.
Metastasis size (>3 cm) was correlated with the recurrence
rate in the CLM and NCLM groups.
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